ArticleBMJ open diabetes research & care2017

Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.

Vincent Lo Re et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.